Should Exact Sciences Stay on Your Investment Watchlist? Q4 2025 Performance Analysis

If you’re actively managing an investment watchlist in the healthcare sector, Exact Sciences Corporation (EXAS) deserves careful consideration following its fourth-quarter 2025 earnings announcement. The company delivered mixed results that highlight both the promise and pitfalls of this rapidly evolving biotech player. Let’s break down whether EXAS merits a prominent place on your watchlist.

Revenue Growth Delivers, But Operating Challenges Persist

Exact Sciences demonstrated solid top-line growth in Q4 2025, with consolidated revenues reaching $878.4 million—a 23% increase year over year on a core basis and exceeding Wall Street expectations by 2.1%. For the full year, revenues climbed to $3.25 billion, representing 18% growth on a core revenue basis compared to 2024.

However, the earnings picture tells a more complicated story. The company reported a net loss of 21 cents per share for the quarter, worse than the 6-cent loss from the prior year. While this loss aligned with analyst consensus, it reflects the company’s ongoing struggle to convert revenue growth into profitability. Full-year EPS came in at 7 cents, a significant improvement from the 23-cent loss in 2024, yet still pointing to operating challenges that investors on your watchlist should monitor closely.

Business Segments Show Mixed Momentum

EXAS generates revenue through two primary business units, and their divergent performance reveals important insights for watchlist investors. The Screening segment, powered by products like Cologuard (colorectal cancer detection) and PreventionGenetics, generated $695.1 million in Q4—a robust 26% year-over-year increase. This strength in preventive oncology testing suggests strong market demand and successful market penetration.

The Precision Oncology segment, which includes the Oncotype product line for therapy selection, posted $183.2 million in quarterly revenue. While still growing at 14% year over year, this segment’s 12% core-basis growth rate represents slower momentum than the Screening division. For watchlist managers, this raises questions about the company’s long-term growth trajectory and whether both segments can sustain double-digit expansion.

Financial Position Tightens Amid Expansion

On the positive side, Exact Sciences’ gross margin expanded significantly, reaching 70.1%—up 106 basis points year over year. This 25% increase in absolute gross profit demonstrates improving operational efficiency and the scalability of the company’s business model, a factor that typically appeals to growth-focused watchlist portfolios.

Yet expenses tell a concerning tale. Research and development spending nearly doubled, climbing 96% to $191.5 million, while sales and marketing expenses rose 18% to $288.5 million. General and administrative costs jumped 14% to $218 million. These mounting expenditures pushed adjusted operating expenses up 30.9% to $698 million, resulting in an adjusted operating loss of $82.2 million—essentially doubling the $40.8 million operating loss from the prior year.

For investors evaluating this stock for their watchlist, the tension is evident: revenue and margin expansion look encouraging, but rapidly rising operating costs threaten to overwhelm these gains in the near term.

Strategic Merger Could Reshape the Investment Story

A significant development that should influence watchlist decisions involves Exact Sciences’ announced merger with Abbott Laboratories. In November 2025, the company entered into a merger agreement, with regulatory reviews currently underway and expected closing targeted for Q2 2026. This transaction represents a potential inflection point for the company’s trajectory.

Abbott’s backing and resources could accelerate Exact Sciences’ path to profitability and strengthen its competitive position in cancer diagnostics. For watchlist purposes, investors should closely monitor regulatory progress and any updates on closing conditions. The merger could either validate current valuations or signal underlying concerns about EXAS’s standalone competitive position.

Cash Position Reflects Operational Demands

Exact Sciences ended Q4 2025 with $964.7 million in cash and marketable securities, down from $1.04 billion at the end of 2024. However, the company generated $491.4 million in cumulative net cash from operating activities—more than double the $210.5 million generated in the prior year. This divergence suggests that while cash burn remains an issue, operational cash generation is accelerating, a positive signal for watchlist investors concerned about runway and financial sustainability.

The Watchlist Verdict

Whether Exact Sciences belongs on your investment watchlist depends on your risk tolerance and investment horizon. The company demonstrates the classic profile of a high-growth biotech: expanding market opportunity in cancer diagnostics, improving unit economics, and solid revenue growth. However, the path to profitability remains unclear, with operating losses widening despite top-line success.

The Abbott merger adds both intrigue and uncertainty to the investment case. A successful close could unlock significant value, but execution risks remain. For conservative watchlist managers, the company may be worth monitoring from the sidelines rather than committing capital. For growth-oriented investors willing to weather near-term profitability challenges, Exact Sciences’ exposure to the expanding oncology testing market could justify an active watchlist position—with the merger as a key catalyst to track in coming quarters.